Systemic lupus erythematosus   

Would concomitant use of a DOAC ease any concerns?

SLE manifestations include arthralgias and cytopenias which are stable. Previously did well on methotrexate, but developed GI side effects. HCQ is on ...

If a patient has received a kidney transplant for SLE-LN and is stable and doing well. Managed by their transplant team and on chronic immunosuppressi...

The case prompting the question is a female in her late teens who was diagnosed with Class IV LN at her prepubescent age and was treated with HCQ and ...

What factors do you discuss when counseling the patient? 

Do you refer all patients with suspected LN, patients with confirmed LN, or patients with specific features (not responding to usual therapy, certain ...

What disease activity index do you find more useful and most practical in a busy clinical setting? How often do you assess it?This question is part of...

For example, when switching from MMF to azathioprine, do you overlap the treatments as you lower the dose of one and add the other?

Would you still plan for lifelong anticoagulation in this scenario? 

This question is part of a collaboration with RheumMadness and is specifically in reference to: Antibodies Before SLE.

Do you do blood work? Or do you rely on review of systems?

(C3 just below normal, C4 undetectable)

What would you suggest to help address these disparities in our own practices?

When would you de-escalate therapy?

(assuming that the malignancy evaluation has been completed and the lymphadenopathy is confirmed to be reactive)

i.e. obstretric APS without thrombosis or SLE

In other words, do we think of TNFi induced lupus and TNFi induced psoriasis as a drug effect or a class effect? 

Do you follow the 2019 EULAR Guidelines that SLE patients with asymptomatic, positive aPL should be on low-dose ASA?

How do you counsel these patients about hormonal agents? 

This question is part of a collaboration with RheumMadness and is specifically in reference to: ADIRA Diet